Novo Nordisk stock jumped Wednesday on better-than-expected fourth-quarter sales, helped by an Ozempic beat.
Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback